ReviewMedicine2025
Granulocytic sarcoma as an initial manifestation of acute promyelocytic leukemia: A case report with literature review.
Review in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleGranulocytic sarcoma (GS) is a rare tumor consisting of myeloid blasts with or without maturation and occurs in sites other than the bone marrow. Due to its low prevalence, clinical cases and pathogenesis need to be studied. Therefore, we present a rare case of humerus GS occurring simultaneously with acute promyelocytic leukemia (APL) and studied a retrospective analysis of clinical characteristics and related treatment strategies, hoping that it could help to standardize the early diagnosis and treatment of APL/GS. PATIENT CONCERNS: We present a case of humerus GS complicated with APL in a 22-year-old woman who experienced pain in right clavicle and shoulder for 6 months without any cause. While the aggravated pain were persistent for 2 months, causing limited movement of her right upper arm. DIAGNOSES: The presence of tumor in her right proximal humerus and end of clavicle was revealed by positron emission tomography-computed tomography. Subsequently, the mass collected during the operation was confirmed to be GS by the pathological immunohistochemical examination. Further progression to APL was based on marrow smears, flow cytometry, fluorescence in situ hybridization, and PML/RARα gene detection. INTERVENTIONS AND OUTCOMES: The patient underwent the tumorectomy, and then received 28-day induction therapy with all-trans retinoic acid (ATRA) (25 mg/m2/d) and arsenic trioxide. The posttreatment bone marrow smear and flow cytometry showed that she was in a complete remission. Consolidation treatment was performed with ATRA 25 mg/m2 PO BID for 2 weeks every 4 weeks and arsenic trioxide 0.16 mg/kg IV 5 days a week for 4 weeks every 8 weeks for a total of 6 cycles. Currently, the patient was routinely followed-up at an outpatient clinic, and has been maintained complete remission for 15 months. LESSONS: We present an uncommon case of a humeral APL/GS, and conducted a comprehensive analysis of 28 cases of APL/GS. Despite the rarity of APL/GS, it should be diagnosed at an early stage. Furthermore, ATRA are recommended in the treatment plan of APL/GS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.